company

TERAPIVAKTEN AS

2070 RÃ…HOLT

Return on Equity
−41,1 %
Current Ratio
−11,5
Debt-to-Equity Ratio
0
Key figures (NOK)2022
Revenue532 000
Net Income−30 000
Total Assets71 000
Total Equity73 000
Income (NOK)2022
Revenue532 000
Expenditure566 000
Operating Profit−34 000
Financial Income0
Financial Costs0
Financial Balance0
Earnings Before Tax−34 000
Tax−5 000
Net Income−30 000
Balance (NOK)2022
Total Fixed Assets48 000
Total Current Assets23 000
Total Assets71 000
Total Retained Equity43 000
Total Equity73 000
Total Long-Term Debt0
Total Current Debt−2 000
Total Equity and Debt71 000
Cash flow (NOK)2022
Sales Income532 000
Other Income0
Revenue532 000
Cost of Goods Sold31 000
Salary Costs13 000
Depreciation0
Impairment0
Expenditure566 000
Operating Profit−34 000
Financial Income0
Financial Costs0
Financial Balance0
Dividends0
Net Income−30 000
Balance details (NOK)2022
Goodwill0
Total Intangible Assets0
Real Eastate0
Machinery and Plant Facilities0
Fixtures48 000
Total Tangible Assets48 000
Total Fiancial Fixed Assets0
Total Fixed Assets48 000
Stock0
Total Investments0
Cash, Bank3 000
Total Current Assets23 000
Total Assets71 000
Total Equity73 000
Short-Term Group Debt0
Total Long-Term Debt0
Creditors0
Unpaid Taxes7 000
Dividends0
Other Current Debt−9 000
Total Current Debt−2 000
Total Equity and Debt71 000
Financial indicators2022
Return on Equity−41,1 %
Debt-to-Equity Ratio0
Operating Profit Margin−6,39 %
Current Ratio−11,5
Quick Ratio−11,5
Equity Ratio1,03
Gross Profit Margin94,17 %
RotateRotate your device to see the full table
HomeIndustriesNew CompaniesAbout
🇳🇴Norsk🇬🇧English